Document is current
Any future updates will be listed below
-
Authors
Arribas López, José Ramón
Ruiz Seco, María Pilar
Fanjul, Francisco
Díaz Pollán, Beatriz
González Ruano Pérez, Patricia
Ferre Beltrán, Adrián
De Miguel Buckley, Rosa
Portillo Horcajada, Laura
De Álvaro Pérez, Cristina
Barroso Santos Carvalho, Paulo Jorge
,
Valdivieso, Juan Luis
Fanjul, Victor
Sarró, Eduard
Cabal-Hierro, Lucía
Menke, Sebastian
Casadevall, David
Marín-Corral, Judith
Polo, Natalia
Taberna, Miren
Riera Jaume, Melchor
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 17 March 2025
First Online: 12 April 2025
Declarations
:
: This study was classified as a ‘non-interventional post-authorization study’ by the Spanish Agency of Medicines and Health Products and was reviewed and approved by the Drug Research Ethics Committee of the Balearic Islands (IB 4731/21 EOm) as the reference Ethics Committee. All methods and analysis followed legal and regulatory requirements and generally accepted research practices described in the latest edition of the Declaration of Helsinki, Good Pharmacoepidemiology Practices, and applicable local regulations. Informed consent was waived by the Drug Research Ethics Committee of the Balearic Islands, as data were retrospectively analyzed from patient EHRs, anonymized, and aggregated in an irreversibly dissociated manner. Data collection and assessment were obtained as part of routine clinical activity and performed in a blinded manner.
: Not applicable.
: JRA reports personal fees from Viiv, Janssen, Gilead, MSD, and Aelix outside the submitted work. MPRS, LPH received personal fees from Gilead for patient review. RDMB reports personal fees (speaker fee and congress attendance grants) from Viiv, and Gilead. CDAP and PJBSC are employees of Gilead Sciences. FFL, BDP, PGRP, AFB, and MRJ declare no competing interests.
